E1505: Similar Survival Across 4 Different Chemotherapy Regimens in Early-Stage, Resected NSCLC

June 3-7, 2016; Chicago, Illinois
DFS and OS outcomes similar in patients with early-stage, resected NSCLC for 4 different cisplatin-based doublet chemotherapy regimens tested.
Format: Microsoft PowerPoint (.ppt)
File Size: 748 KB
Released: June 8, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Downloadable slideset on the use of neoadjuvant immunotherapy in resectable early-stage lung cancer, from Clinical Care Options (CCO)

Released: December 1, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on EGFR Exon 20–Altered NSCLC.

Enriqueta Felip, MD Alexander Spira, MD, PhD, FACP Released: December 1, 2021

PDF transcript of a podcast where lung cancer experts answer clinical questions on evolving immunotherapy strategies for NSCLC, from Clinical Care Options (CCO)

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: December 1, 2021

Jonathan Spicer, MD, PhD, FRCS, explores the use of neoadjuvant immunotherapy in resectable early-stage lung cancer from a surgeon’s perspective in this text module from Clinical Care Options (CCO)

person default Jonathan Spicer, MD, PhD, FRCS Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: December 1, 2021 Expired: November 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue